Research ArticleNew Horizons Symposiums

How Should Aerosols Be Delivered During Invasive Mechanical Ventilation?

Rajiv Dhand
Respiratory Care October 2017, 62 (10) 1343-1367; DOI: https://doi.org/10.4187/respcare.05803

References

  1. 1.↵
    1. Wunsch H,
    2. Linde-Zwirble WT,
    3. Angus DC,
    4. Hartman ME,
    5. Milbrandt EB,
    6. Kahn JM
    . The epidemiology of mechanical ventilation use in the United States. Crit Care Med 2010;38(10):1947–1953.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    American Association for Respiratory Care. Aerosol consensus statement: 1991. Respir Care 1991;36(9):916–921.
    OpenUrlPubMed
  3. 3.↵
    1. MacIntyre NR,
    2. Silver RM,
    3. Miller CW,
    4. Schuler F,
    5. Coleman RE
    . Aerosol delivery in intubated, mechanically ventilated patients. Crit Care Med 1985;13(2):81–84.
    OpenUrlPubMedWeb of Science
  4. 4.↵
    1. Fuller HD,
    2. Dolovich MB,
    3. Posmituck G,
    4. Pack WW,
    5. Newhouse MT
    . Pressurized aerosol versus jet aerosol delivery to mechanically ventilated patients. Comparison of dose to the lungs. Am Rev Respir Dis 1990;141(2):440–444.
    OpenUrlPubMedWeb of Science
  5. 5.↵
    1. Dhand R,
    2. Tobin MJ
    . Inhaled bronchodilator therapy in mechanically ventilated patients. Am J Respir Crit Care Med 1997;156(1):3–10.
    OpenUrlPubMedWeb of Science
  6. 6.↵
    1. Dhand R
    . Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care 47(12):1406–1416, 2002; discussion 1416-1418.
    OpenUrlPubMed
  7. 7.↵
    1. Dolovich MB,
    2. Dhand R
    . Aerosol drug delivery: developments in device design and clinical use. Lancet 2011;377(9770):1032–1045.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Laube BL,
    2. Janssens HM,
    3. de Jongh FHC,
    4. Devadason S,
    5. Dhand R,
    6. Diot P,
    7. et al
    . ERS/ISAM Task Force Report: What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011;37(6):1308–1331.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Ari A,
    2. Fink JB,
    3. Dhand R
    . Inhalation therapy in patients receiving mechanical ventilation: an update. J Aerosol Med Pulm Drug Deliv 2012;25(6):319–332.
    OpenUrlPubMed
  10. 10.↵
    1. Fink JB,
    2. Dhand R,
    3. Duarte AG,
    4. Jenne JW,
    5. Tobin MJ
    . Aerosol delivery from a metered-dose inhaler during mechanical ventilation. An in-vitro model. Am J Respir Crit Care Med 1996;154(2 Pt1):382–387.
    OpenUrlPubMedWeb of Science
  11. 11.↵
    1. Fink JB,
    2. Dhand R,
    3. Grychowski J,
    4. Fahey PJ,
    5. Tobin MJ
    . Reconciling in-vitro and in-vivo measurements of aerosol delivery from a metered-dose inhaler during mechanical ventilation, and defining efficiency enhancing factors. Am J Respir Crit Care Med 1999;159(1):63–68.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Vecellio L,
    2. Guérin C,
    3. Grimbert D,
    4. De Monte M,
    5. Diot P
    . In vitro study and semiempirical model for aerosol delivery control during mechanical ventilation. Intensive Care Med 2005;31(6):871–876.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. O'Riordan TG,
    2. Palmer LB,
    3. Smaldone GC
    . Aerosol deposition in mechanically ventilated patients: optimizing nebulizer delivery. Am J Respir Crit Care Med 1994;149(1):214–219.
    OpenUrlPubMedWeb of Science
  14. 14.↵
    1. Duarte AG,
    2. Dhand R,
    3. Reid R,
    4. Fink JB,
    5. Fahey PJ,
    6. Tobin MJ,
    7. Jenne JW
    . Serum albuterol levels in mechanically ventilated patients and healthy subjects after metered-dose inhaler administration. Am J Respir Crit Care Med 1996;154(6 Pt1):1658–1663.
    OpenUrlPubMed
  15. 15.↵
    1. Marik P,
    2. Hogan J,
    3. Krikorian J
    . A comparison of bronchodilator therapy delivered by nebulization and metered-dose inhaler in mechanically ventilated patients. Chest 1999;115(6):1653–1657.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Miller DD,
    2. Amin MM,
    3. Palmer LB,
    4. Shah AR,
    5. Smaldone GC
    . Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation. Am J Respir Crit Care Med 2003;168(10):1205–1209.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Dhand R,
    2. Duarte AG,
    3. Jubran A,
    4. Jenne JW,
    5. Fink JB,
    6. Fahey PJ,
    7. Tobin MJ
    . Dose-response to bronchodilator delivered by metered-dose inhaler in ventilator-supported patients. Am J Respir Crit Care Med 1996;154(2 Pt1):388–393.
    OpenUrlPubMedWeb of Science
  18. 18.↵
    1. Duarte AG,
    2. Momii K,
    3. Bidani A
    . Bronchodilator therapy with metered-dose inhaler and spacer versus nebulizer in mechanically ventilated patients: comparison of magnitude and duration of response. Respir Care 2000;45(7):817–823.
    OpenUrlPubMed
  19. 19.↵
    1. Manthous CA,
    2. Hall JB,
    3. Schmidt GA,
    4. Wood LD
    . Metered-dose inhaler versus nebulized albuterol in mechanically ventilated patients. Am Rev Respir Dis 1993;148(6 Pt 1):1567–1570.
    OpenUrlPubMedWeb of Science
  20. 20.↵
    1. Manthous CA,
    2. Chatila W,
    3. Schmidt GA,
    4. Hall JB
    . Treatment of bronchospasm by metered-dose inhaler albuterol in mechanically ventilated patients. Chest 1995;107(1):210–213.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Dolovich MB,
    2. Ahrens RC,
    3. Hess DR,
    4. Anderson P,
    5. Dhand R,
    6. Rau JL,
    7. et al
    . Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/ American College of Asthma, Allergy, and Immunology. Chest 2005;127(1):335–371.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Mouloudi E,
    2. Maliotakis C,
    3. Kondili E,
    4. Kafetzakis A,
    5. Georgopoulos D
    . Duration of salbutamol-induced bronchodilation delivered by metered-dose inhaler in mechanically ventilated COPD patients. Monaldi Arch Chest Dis 2001;56(3):189–194.
    OpenUrlPubMed
  23. 23.↵
    1. Dhand R,
    2. Guntur VP
    . How best to deliver aerosol medications to mechanically ventilated patients. Clin Chest Med 2008;29(2):277–296.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Georgopoulos D,
    2. Mouloudi E,
    3. Kondili E,
    4. Klimathianaki M
    . Bronchodilator delivery with metered-dose inhaler during mechanical ventilation. Crit Care 2000;4(4):227–234.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Dhand R
    . Inhalation therapy with metered-dose inhalers and dry powder inhalers in mechanically ventilated patients. Respir Care 2005;50(10):1331–1334; discussion 1344-1345.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Rau JL,
    2. Dunlevy CL,
    3. Hill RL
    . A comparison of inline MDI actuators for delivery of a beta agonist and a corticosteroid with a mechanically ventilated lung model. Respir Care 1998;43(9):705–712.
    OpenUrl
  27. 27.↵
    1. Rau JL,
    2. Harwood RJ,
    3. Groff JL
    . Evaluation of a reservoir device for metered-dose bronchodilator delivery to intubated adults. An in vitro study. Chest 1992;102(3):924–930.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Dhand R,
    2. Tobin MJ
    . Bronchodilator delivery with metered-dose inhalers in mechanically ventilated patients. Eur Respir J 1996;9(3):585–595.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Taylor RH,
    2. Lerman J,
    3. Chambers C,
    4. Dolovich M
    . Dosing efficiency and particle-size characteristics of pressurized metered-dose inhaler aerosols in narrow catheters. Chest 1993;103(3):920–924.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Diot P,
    2. Morra L,
    3. Smaldone GC
    . Albuterol delivery in a model of mechanical ventilation. Comparison of metered-dose inhaler and nebulizer efficiency. Am J Respir Crit Care Med 1995;152(4 pt1):1391–1394.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Thomas SH,
    2. O'Doherty MJ,
    3. Page CJ,
    4. Treacher DF,
    5. Nunan TO
    . Delivery of ultrasonic nebulized aerosols to a lung model during mechanical ventilation. Am Rev Respir Dis 1993;148(4 Pt1):872–877.
    OpenUrlPubMedWeb of Science
  32. 32.↵
    1. Fink JB
    . Metered-dose inhalers, dry powder inhalers and transitions. Respir Care 2000;45(6):623–635.
    OpenUrlPubMed
  33. 33.↵
    1. Everard ML,
    2. Devadason SG,
    3. Summers QA,
    4. Le Souëf PN
    . Factors affecting total and “respirable” dose delivered by a salbutamol metered dose inhaler. Thorax 1995;50(7):746–749.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Niven RW,
    2. Kacmarek RM,
    3. Brain JD,
    4. Peterfreund RA
    . Small bore nozzle extensions to improve the delivery efficiency of drugs from metered-dose inhalers: laboratory evaluation. Am Rev Respir Dis 1993;147(6 Pt1):1590–1594.
    OpenUrlPubMedWeb of Science
  35. 35.↵
    1. Spahr-Schopfer IA,
    2. Lerman J,
    3. Cutz E,
    4. Newhouse MT,
    5. Dolovich M
    . Proximate delivery of a large experimental dose from salbutamol MDI induces epithelial airway lesions in intubated rabbits. Am J Respir Crit Care Med 1994;150(3):790–794.
    OpenUrlPubMedWeb of Science
  36. 36.↵
    1. Dhand R,
    2. Jubran A,
    3. Tobin MJ
    . Bronchodilator delivery by metered-dose inhaler in ventilator-supported patients. Am J Respir Crit Care Med 1995;151(6):1827–1833.
    OpenUrlPubMedWeb of Science
  37. 37.↵
    1. Ari A,
    2. Areabi H,
    3. Fink JB
    . Evaluation of aerosol generator devices at 3 locations in humidified and non-humidified circuits during adult mechanical ventilation. Respir Care 2010;55(7):837–844.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Rau JL
    . Design principles of liquid nebulization devices currently in use. Respir Care 47(11):1257–1275, 2002; discussion 1275-1278.
    OpenUrlPubMed
  39. 39.↵
    1. Hickey AJ
    1. Dalby RN,
    2. Tiano SL,
    3. Hickey AJ
    . Medical devices for the delivery of therapeutic aerosols to the lungs. In: Hickey AJ, ed. Inhalation Aerosols: Physical and Biological Basis for Therapy. New York: Marcel Dekker, 1996;441–473.
  40. 40.↵
    1. Hess DR
    . Nebulizers: principles and performance. Respir Care 2000;45(6):609–622.
    OpenUrlPubMed
  41. 41.↵
    1. Alvine GF,
    2. Rodgers P,
    3. Fitzsimmons KM,
    4. Ahrens RC
    . Disposable jet nebulizers. How reliable are they? Chest 1992;101(2):316–319.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.
    1. Loffert DT,
    2. Ikle D,
    3. Nelson HS
    . A comparison of commercial jet nebulizers. Chest 1994;106(6):1788–1792.
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    1. Hess D,
    2. Fisher D,
    3. Williams P,
    4. Pooler S,
    5. Kacmarek RM
    . Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand. Chest 1996;110(2):498–505.
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.↵
    1. Phipps PR,
    2. Gonda I
    . Droplets produced by medical nebulizers. Some factors affecting their size and solute concentration. Chest 1990;97(6):1327–1332.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    1. Steckel H,
    2. Eskandar F
    . Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers. Eur J Pharm Sci 2003;19(5):443–455.
    OpenUrlPubMed
  46. 46.↵
    1. Watts AB,
    2. McConville JT,
    3. Williams RO
    . Current therapies and technological advances in aqueous aerosol drug delivery. Drug Dev Ind Pharm 2008;34(9):913–922.
    OpenUrlPubMed
  47. 47.↵
    1. Kemming GI,
    2. Kreyling W,
    3. Habler O,
    4. Merkel M,
    5. Kleen M,
    6. Welte M,
    7. et al
    . Aerosol production and aerosol droplet size distribution during mechanical ventilation (IPPV) with a new ultrasonic nebulizer. Eur J Med Res 1996;1(7):321–327.
    OpenUrlPubMed
  48. 48.↵
    1. Harvey CJ,
    2. O'Doherty MJ,
    3. Page CJ,
    4. Thomas SH,
    5. Nunan TO,
    6. Treacher DF
    . Comparison of jet and ultrasonic nebulizer pulmonary aerosol deposition during mechanical ventilation. Eur Respir J 1997;10(4):905–909.
    OpenUrlAbstract
  49. 49.↵
    1. Williams L,
    2. Fletcher GC,
    3. Daniel M,
    4. Kinsella J
    . A simple in vitro method for the evaluation of an ultrasonic nebulizer for drug delivery to intubated, ventilated patients and the effect of nebulizer and ventilator settings on the uptake of fluid from the nebulizer chamber. Eur J Anaesthesiol 1999;16(7):479–484.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. Phillips GD,
    2. Millard FJL
    . The therapeutic use of ultrasonic nebulizers in acute asthma. Respir Med 1994;88(5):387–389.
    OpenUrlPubMed
  51. 51.↵
    1. O'Doherty MJ,
    2. Thomas SH,
    3. Page CJ,
    4. Treacher DF,
    5. Nunan TO
    . Delivery of a nebulized aerosol to a lung model during mechanical ventilation. Effect of ventilator settings and nebulizer type, position, and volume of fill. Am Rev Respir Dis 1992;146(2):383–388.
    OpenUrlPubMedWeb of Science
  52. 52.↵
    1. ElHansy MH,
    2. Boules ME,
    3. Farid H,
    4. Chrystyn H,
    5. El-Maraghi SK,
    6. Al-Kholy MB,
    7. et al
    . In vitro aerodynamic characteristics of aerosol delivered from different inhalation methods in mechanical ventilation. Pharm Dev Technol 2016;30:1–6.
    OpenUrl
  53. 53.
    1. Diot P,
    2. Magro P,
    3. Vecellio L,
    4. Smaldone GC
    . Advances in our understanding of aerosolized iloprost for pulmonary hypertension. J Aerosol Med 2006;19(3):406–407.
    OpenUrlPubMed
  54. 54.↵
    1. Smaldone GC
    . Advances in aerosols: adult respiratory disease. J Aerosol Med 2006;19(1):36–46.
    OpenUrlCrossRefPubMedWeb of Science
  55. 55.↵
    1. Van Dyke RE,
    2. Nikander K
    . Delivery of iloprost inhalation solution with the HaloLite, Prodose, and I-neb Adaptive Aerosol Delivery systems: an in vitro study Respir Care 2007;52(2):184–190.
    OpenUrlAbstract/FREE Full Text
  56. 56.↵
    1. Waldrep JC,
    2. Dhand R
    . Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation. Curr Drug Deliv 2008;5(2):114–119.
    OpenUrlCrossRefPubMed
  57. 57.↵
    1. Waldrep JC,
    2. Berlinski A,
    3. Dhand R
    . Comparative analysis of methods to measure aerosols generated by a vibrating mesh nebulizer. J Aerosol Med 2007;20(3):310–319.
    OpenUrlPubMed
  58. 58.↵
    1. Johnson JC,
    2. Waldrep JC,
    3. Guo J,
    4. Dhand R
    . Aerosol delivery of recombinant human DNase I: in vitro comparison of a vibrating-mesh nebulizer with a jet nebulizer. Respir Care 2008;53(12):1703–1708.
    OpenUrlAbstract/FREE Full Text
  59. 59.↵
    1. Vincent J
    1. Ruickbie S,
    2. Hall A,
    3. Ball J
    . Therapeutic aerosols in mechanically ventilated patients. In: Vincent J, editor. Annual Update in Intensive Care and Emergency Medicine 2011. Berlin, Heidelberg: Springer; 2011. p. 197–206.
  60. 60.↵
    1. Rubin BK
    . Pediatric aerosol therapy: new devices and new drugs. Respir Care 56(9):1411–1421, 2011; discussion 1421-1423.
    OpenUrlAbstract/FREE Full Text
  61. 61.↵
    1. Gowda AA,
    2. Cuccia AD,
    3. Smaldone GC
    . Reliability of vibrating mesh technology. Respir Care 2017;62(1):65–69.
    OpenUrlAbstract/FREE Full Text
  62. 62.↵
    1. Ehrmann S,
    2. Roche-Campo F,
    3. Bodet-Contentin L,
    4. Razazi K,
    5. Dugernier J,
    6. Trenado-Alvarez J,
    7. et al
    . Aerosol therapy in intensive and intermediate care units: prospective observation of 2808 critically ill patients. Intensive Care Med 2016;42(2):192–201.
    OpenUrlCrossRefPubMed
  63. 63.↵
    1. Ehrmann S,
    2. Lyazidi A,
    3. Louis B,
    4. Isabey D,
    5. Le Pennec D,
    6. Brochard L,
    7. Apriou-Sbirlea G
    . Ventilator-integrated jet nebulization systems: tidal volume control and efficiency of synchronization. Respir Care 2014;59(10):1508–1516.
    OpenUrlAbstract/FREE Full Text
  64. 64.↵
    1. Dhand R,
    2. Sohal H
    . Pulmonary Drug Delivery System for inhalation therapy in mechanically ventilated patients. Expert Rev Med Devices 2008;5(1):9–20.
    OpenUrlCrossRefPubMed
  65. 65.↵
    1. Niederman MS,
    2. Chastre J,
    3. Corkery K,
    4. Fink JB,
    5. Luyt CE,
    6. García MS
    . BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med 2012;38(2):263–271.
    OpenUrlCrossRefPubMed
  66. 66.↵
    1. Ari A,
    2. Atalay OT,
    3. Harwood R,
    4. Sheard MM,
    5. Aljamhan EA,
    6. Fink JB
    . Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation. Respir Care 2010;55(7):845–851.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    1. O'Riordan TG,
    2. Greco MJ,
    3. Perry RJ,
    4. Smaldone GC
    . Nebulizer function during mechanical ventilation. Am Rev Respir Dis 1992;145(5):1117–1122.
    OpenUrlCrossRefPubMedWeb of Science
  68. 68.↵
    1. Hughes JM,
    2. Saez J
    . Effects of nebulizer mode and position in a mechanical ventilator circuit on dose efficiency. Respir Care 1987;32(12):1131–1135.
    OpenUrl
  69. 69.↵
    1. Wan GH,
    2. Lin HL,
    3. Fink JB,
    4. Chen YH,
    5. Wang WJ,
    6. Chiu YC,
    7. et al
    . In vitro evaluation of aerosol delivery by different nebulization modes in pediatric and adult mechanical ventilators. Respir Care 2014;59(10):1494–1500.
    OpenUrlAbstract/FREE Full Text
  70. 70.↵
    1. Moraine JJ,
    2. Truflandier K,
    3. Vandenbergen N,
    4. Berre J,
    5. Melot C,
    6. Vincent JL
    . Placement of the nebulizer before the humidifier during mechanical ventilation: effect on aerosol delivery. Heart Lung 2009;38(5):435–439.
    OpenUrlPubMed
  71. 71.↵
    1. Dhand R
    . Aerosol therapy during mechanical ventilation: getting ready for prime time. Am J Respir Crit Care Med 2003;168(10):1148–1149.
    OpenUrlPubMed
  72. 72.↵
    1. Siobal MS,
    2. Kallet RH,
    3. Pittet J-F,
    4. Warnecke EL,
    5. Kraemer RW,
    6. Venkayya RV,
    7. Tang JF
    . Description and evaluation of a delivery system for aerosolized prostacyclin. Respir Care 2003;48(8):742–753.
    OpenUrlAbstract/FREE Full Text
  73. 73.↵
    1. Pitance L,
    2. Vecellio L,
    3. Leal T,
    4. Reychler G,
    5. Reychler H,
    6. Liistro G
    . Delivery efficacy of a vibrating mesh nebulizer and a jet nebulizer under different configurations. J Aerosol Med Pulm Drug Deliv 2010;23(6):389–396.
    OpenUrlPubMed
  74. 74.↵
    1. Dhand R
    . Aerosol delivery during mechanical ventilation: from basic techniques to new devices. J Aerosol Med Pulm Drug Deliv 2008;21(1):45–60.
    OpenUrlCrossRefPubMedWeb of Science
  75. 75.↵
    1. Dellweg D,
    2. Wachtel H,
    3. Höhn E,
    4. Pieper MP,
    5. Barchfeld T,
    6. Köhler D,
    7. Glaab T
    . In vitro validation of a Respimat® adapter for delivery of inhaled bronchodilators during mechanical ventilation. J Aerosol Med Pulm Drug Deliv 2011;24(6):285–292.
    OpenUrlPubMed
  76. 76.↵
    1. Everard ML,
    2. Devadason SG,
    3. Le Souef PN
    . In vitro assessment of drug delivery through an endotracheal tube using a dry powder inhaler delivery system. Thorax 1996;51(1):75–77.
    OpenUrlAbstract/FREE Full Text
  77. 77.↵
    1. Jashnani RN,
    2. Byron PR,
    3. Dalby RN
    . Testing of dry powder aerosol formulations in different environmental conditions. Int J Pharm 1995;113(1):123–130.
    OpenUrlCrossRef
  78. 78.↵
    1. Tronde A,
    2. Baran G,
    3. Eirefelt S,
    4. Lennernäs H,
    5. Bengtsson UH
    . Miniaturized nebulization catheters: a new approach for delivery of defined aerosol doses to the rat lung. J Aerosol Med 2002;15(3):283–296.
    OpenUrlCrossRefPubMedWeb of Science
  79. 79.↵
    1. Köping-Höggård M,
    2. Issa MM,
    3. Köhler T,
    4. Tronde A,
    5. Vårum Km,
    6. Artursson P
    . A miniaturized nebulization catheter for improved gene delivery to the mouse lung. J Gene Med 2005;7(9):1215–1222.
    OpenUrlPubMed
  80. 80.↵
    1. Selting K,
    2. Waldrep JC,
    3. Reinero C,
    4. Branson K,
    5. Gustafson D,
    6. Kim DY,
    7. et al
    . Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe intracorporeal nebulization catheter. J Aerosol Med Pulm Drug Deliv 2008;21(3):255–268.
    OpenUrlPubMed
  81. 81.↵
    1. Selting K,
    2. Essman S,
    3. Reinero C,
    4. Branson KR,
    5. Henry CJ,
    6. Owen N,
    7. et al
    . Targeted combined aerosol chemotherapy in dogs and radiologic toxicity grading. J Aerosol Med Pulm Drug Deliv 2011;24(1):43–48.
    OpenUrlPubMed
  82. 82.↵
    1. Guerin C,
    2. Chevre A,
    3. Dessirier P,
    4. Poncet T,
    5. Becquemin MH,
    6. Dequin PF,
    7. et al
    . Inhaled fenoterol-ipratropium bromide in mechanically ventilated patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159(4 Pt1):1036–1042.
    OpenUrlPubMedWeb of Science
  83. 83.↵
    1. Tobin MJ
    1. Dhand R
    . Bronchodilator Therapy. Tobin MJ, editor. Principles and Practice of Mechanical Ventilation. 3rd edition. New York: McGraw Hill; 2013:1419–1446.
  84. 84.↵
    1. Gilmore T
    . Use of a metered-dose inhaler compared with a vibrating mesh nebulizer during mechanical ventilation: does it really matter? Respir Care 2017;62(4):513–514.
    OpenUrlFREE Full Text
  85. 85.↵
    1. Craven DE,
    2. Lichtenberg DA,
    3. Goularte TA,
    4. Make BJ,
    5. McCabe WR
    . Contaminated medication nebulizers in mechanical ventilator circuits: source of bacterial aerosols. Am J Med 1984;77(5):834–838.
    OpenUrlCrossRefPubMedWeb of Science
  86. 86.↵
    1. Hamill RJ,
    2. Houston ED,
    3. Georghiou PR,
    4. Wright CE,
    5. Koza MA,
    6. Cadle RM,
    7. et al
    . An outbreak of Burkholderia (formerly Pseudomonas) cepacia respiratory tract colonization and infection associated with nebulized albuterol therapy. Ann Intern Med 1995;122(10):762–766.
    OpenUrlPubMedWeb of Science
  87. 87.↵
    1. Ballard J,
    2. Lugo RA,
    3. Salyer JW
    . A survey of albuterol administration practices in intubated patients in the neonatal intensive care unit. Respir Care 2002;47(1):31–38.
    OpenUrlPubMed
  88. 88.↵
    1. Chang LH,
    2. Honiden S,
    3. Haithcock JA,
    4. Das AM,
    5. Short KA,
    6. Nierman DM,
    7. Carson SS
    . Utilization of bronchodilators in ventilated patients without obstructive airways disease. Respir Care 2007;52(2):154–158.
    OpenUrlAbstract/FREE Full Text
  89. 89.↵
    1. Summer W,
    2. Elston R,
    3. Tharpe L,
    4. Nelson S,
    5. Haponik EF
    . Aerosol bronchodilator delivery methods. Relative impact on pulmonary function and cost of respiratory care. Arch Intern Med 1989;149(3):618–623.
    OpenUrlCrossRefPubMedWeb of Science
  90. 90.
    1. Bowton DL,
    2. Goldsmith WM,
    3. Haponik EF
    . Substitution of metered-dose inhalers for hand-held nebulizers. Success and cost savings in a large, acute-care hospital. Chest 1992;101(2):305–308.
    OpenUrlCrossRefPubMedWeb of Science
  91. 91.↵
    1. Ely EW,
    2. Baker AM,
    3. Evans GW,
    4. Haponik EF
    . The distribution of costs of care in mechanically ventilated patients with chronic obstructive pulmonary disease. Crit Care Med 2000;28(2):408–413.
    OpenUrlCrossRefPubMedWeb of Science
  92. 92.↵
    1. Holland A,
    2. Smith F,
    3. Penny K,
    4. McCrossan G,
    5. Veitch L,
    6. Nicholson C
    . Metered dose inhalers versus nebulizers for aerosol bronchodilator delivery for adult patients receiving mechanical ventilation in critical care units. Cochrane Database Syst Rev. 2013 Jun 6;(6):CD008863.
  93. 93.↵
    1. Dhand R,
    2. Mercier E
    . Effective inhaled drug administration to mechanically ventilated patients. Expert Opin Drug Deliv 2007;4(1):47–61.
    OpenUrlCrossRefPubMed
  94. 94.↵
    1. Ehrmann S,
    2. Roche-Campo F,
    3. Sferrazza Papa GF,
    4. Isabey D,
    5. Brochard L,
    6. Apiou-Sbirlea G
    ; REVA Research Network. Aerosol therapy during mechanical ventilation: an international survey. Intensive Care Med 2013;39(6):1048–1056.
    OpenUrlCrossRefPubMed
  95. 95.↵
    1. Boucher BA,
    2. Kuhl DA,
    3. Coffey BC,
    4. Fabian TC
    . Drug use in a trauma intensive-care unit. Am J Hosp Pharm 1990;47(4):805–810.
    OpenUrlAbstract
  96. 96.↵
    1. Wollam PJ,
    2. Kasper CL,
    3. Bishop MJ,
    4. Pierson DJ
    . Prediction and assessment of bronchodilator response in mechanically ventilated patients. Respir Care 1994;39(7):730–737.
    OpenUrl
  97. 97.↵
    1. Tzoufi M,
    2. Mentzelopoulos SD,
    3. Roussos C,
    4. Armaganidis A
    . The effects of nebulized salbutamol, external positive end-expiratory pressure, and their combination on respiratory mechanics, hemodynamics, and gas exchange in mechanically ventilated chronic obstructive pulmonary disease patients. Anesth Analg 2005;101(3):843–850.
    OpenUrlCrossRefPubMed
  98. 98.↵
    1. Gay PC,
    2. Rodarte JR,
    3. Tayyab M,
    4. Hubmayr RD
    . Evaluation of bronchodilator responsiveness in mechanically ventilated patients. Am Rev Respir Dis 1987;136(4):880–885.
    OpenUrlPubMedWeb of Science
  99. 99.↵
    1. Wright PE,
    2. Carmichael LC,
    3. Bernard GR
    . Effect of bronchodilators on lung mechanics in the acute respiratory distress syndrome (ARDS). Chest 1994;106(5):1517–1523.
    OpenUrlCrossRefPubMedWeb of Science
  100. 100.↵
    1. Morina P,
    2. Herrera M,
    3. Venegas J,
    4. Mora D,
    5. Rodríguez M,
    6. Pino E
    . Effects of nebulized salbutamol on respiratory mechanics in adult respiratory distress syndrome. Intensive Care Med 1997;23(1):58–64.
    OpenUrlCrossRefPubMedWeb of Science
  101. 101.↵
    1. Mancebo J,
    2. Amaro P,
    3. Lorino H,
    4. Lemaire F,
    5. Harf A,
    6. Brochard L
    . Effects of albuterol inhalation on the work of breathing during weaning from mechanical ventilation. Am Rev Respir Dis 1991;144(1):95–100.
    OpenUrlPubMedWeb of Science
  102. 102.↵
    1. Fernandez A,
    2. Munoz J,
    3. de la Calle B,
    4. Alia I,
    5. Ezpeleta A,
    6. de la Cal MA,
    7. Reyes A
    . Comparison of one versus two bronchodilators in ventilated COPD patients. Intensive Care Med 1994;20(3):199–202.
    OpenUrlCrossRefPubMedWeb of Science
  103. 103.↵
    1. Bennett WD
    . Effect of beta-adrenergic agonists on mucociliary clearance. J Allergy Clin Immunol 2002;110(6 Suppl):S291–S297.
    OpenUrlCrossRefPubMed
  104. 104.↵
    1. McAuley DF,
    2. Frank JA,
    3. Fang X,
    4. Matthay MA
    . Clinically relevant concentrations of beta2-adrenergic agonists stimulate maximal cyclic adenosine monophosphate-dependent airspace fluid clearance and decrease pulmonary edema in experimental acid-induced lung injury. Crit Care Med 2004;32(7):1470–1476.
    OpenUrlCrossRefPubMedWeb of Science
  105. 105.↵
    1. Matthay MA,
    2. Brower RG,
    3. Carson S,
    4. Douglas IS,
    5. Eisner M,
    6. et al
    National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Matthay MA, Brower RG, Carson S, Douglas IS, Eisner M, et al. Randomized, placebo-controlled clinical trial of an aerosolized β2-agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011;184(5):561–568.
    OpenUrlCrossRefPubMedWeb of Science
  106. 106.↵
    1. Abramson MJ,
    2. Walters J,
    3. Walters EH
    . Adverse effects of beta-agonists: are they clinically relevant? Am J Respir Med 2003;2(4):287–297.
    OpenUrlCrossRefPubMed
  107. 107.
    1. Kleerup EC,
    2. Tashkin DP,
    3. Cline AC,
    4. Ekholm BP
    . Cumulative dose-response study of non-CFC propellant HFA-134a salbutamol sulfate metered-dose inhaler in patients with asthma. Chest 1996;109(3):702–707.
    OpenUrlCrossRefPubMedWeb of Science
  108. 108.↵
    1. Ramsdell JW,
    2. Colice GL,
    3. Ekholm BP,
    4. Klinger NM
    . Cumulative dose response study comparing HFA-134a albuterol sulfate and conventional CFC albuterol in patients with asthma. Ann Allergy Asthma Immunol 1998;81(6):593–599.
    OpenUrlPubMedWeb of Science
  109. 109.↵
    1. Dhand R
    . Bronchodilator therapy in mechanically ventilated patients: patient selection and clinical outcomes. Respir Care 2007;52(2):152–153.
    OpenUrlFREE Full Text
  110. 110.↵
    1. Le Brun PP,
    2. de Boer AH,
    3. Heijerman HG,
    4. Frijlink HW
    . A review of the technical aspects of drug nebulization. Pharm World Sci 2000;22(3):75–81.
    OpenUrlCrossRefPubMedWeb of Science
  111. 111.↵
    1. Luyt CE,
    2. Clavel M,
    3. Guntupalli K,
    4. Johannigman J,
    5. Kennedy JI,
    6. Wood C,
    7. et al
    . Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Critical Care 2009;13:R200. doi:10.1186/cc8206.
  112. 112.↵
    1. Kalil AC,
    2. Metersky ML,
    3. Klompas M,
    4. Muscedere J,
    5. Sweeney DA,
    6. Palmer LB,
    7. et al
    . Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016;63(5):e61–e111.
    OpenUrlCrossRefPubMed
  113. 113.↵
    1. Solé-Lleonart C,
    2. Rouby JJ,
    3. Blot S,
    4. Poulakou G,
    5. Chastre J,
    6. Palmer LB,
    7. et al
    . Nebulization of antiinfective agents in invasively mechanically ventilated adults: a systematic review and meta-analysis. Anesthesiology 2017;126(5):890–908.
    OpenUrl
  114. 114.↵
    1. Kollef MH,
    2. Ricard JD,
    3. Roux D,
    4. Francois B,
    5. Ischaki E,
    6. Rozgonyi Z,
    7. et al
    . A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of gram-negative ventilator-associated pneumonia: IASIS Trial. Chest 2017;151(6):1239–1246.
    OpenUrl
  115. 115.↵
    1. Squara P,
    2. Dhainaut JF,
    3. Artigas A,
    4. Carlet J
    . Hemodynamic profile in severe ARDS: results of the European Collaborative ARDS Study. Intensive Care Med 1998;24(10):1018–1028.
    OpenUrlCrossRefPubMedWeb of Science
  116. 116.↵
    1. DiBlasi RM,
    2. Meyer TR,
    3. Hess DR
    . Evidence-based clinical practice guidelines: inhaled nitric oxide for neonates with acute hypoxic respiratory failure. Respir Care 2010;55(12):1717–1745.
    OpenUrlAbstract/FREE Full Text
  117. 117.↵
    1. Puri N,
    2. Dellinger RP
    . Inhaled nitric oxide and inhaled prostacyclin in acute respiratory distress syndrome: what is the evidence? Crit Care Clin 2011;27(3):561–587.
    OpenUrlCrossRefPubMed
  118. 118.↵
    1. Bihari D,
    2. Smithies M,
    3. Gimson A,
    4. Tinker J
    . The effects of vasodilation with prostacyclin on oxygen delivery and uptake in critically ill patients. N Engl J Med 1987;317(7):397–403.
    OpenUrlCrossRefPubMedWeb of Science
  119. 119.↵
    1. Radermacher P,
    2. Santak B,
    3. Wust HJ,
    4. Tarnow J,
    5. Falke KJ
    . Prostacyclin for the treatment of pulmonary hypertension in the adult respiratory distress syndrome: effects on pulmonary capillary pressure and ventilation-perfusion distributions. Anesthesiology 1990;72(2):238–244.
    OpenUrlPubMedWeb of Science
  120. 120.↵
    1. Haraldsson A,
    2. Kieler-Jensen N,
    3. Ricksten SE
    . Inhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation: a pharmacodynamic study. J Cardiothorac Vasc Anesth 1996;10(7):864–868.
    OpenUrlCrossRefPubMedWeb of Science
  121. 121.↵
    1. Meyer J,
    2. Theilmeier G,
    3. Van Aken H,
    4. Bone HG,
    5. Busse H,
    6. Waurick R,
    7. Hinder F,
    8. Booke M
    . Inhaled prostaglandin E1 for the treatment of acute lung injury in severe multiple organ failure. Anesth Analg 1998;86(4):753–758.
    OpenUrlCrossRefPubMedWeb of Science
  122. 122.↵
    1. Walmrath D,
    2. Schneider T,
    3. Schermuly R,
    4. Olschewski H,
    5. Grimminger F,
    6. Seeger W
    . Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in adult respiratory distress syndrome. Am J Respir Crit Care Med 1996;153(3):991–996.
    OpenUrlCrossRefPubMedWeb of Science
  123. 123.
    1. Zwissler B,
    2. Kemming G,
    3. Habler O,
    4. Kleen M,
    5. Merkel M,
    6. Haller M,
    7. et al
    . Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med 1996;154(6Pt1):1671–1677.
    OpenUrlCrossRefPubMedWeb of Science
  124. 124.↵
    1. Putensen C,
    2. Hormann C,
    3. Kleinsasser A,
    4. Putensen-Himmer G
    . Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1998;157(6 Pt 1):1743–1747.
    OpenUrlPubMedWeb of Science
  125. 125.↵
    1. Fuller BM,
    2. Mohr NM,
    3. Skrupky L,
    4. Fowler S,
    5. Kollef MH,
    6. Carpenter CR
    . The use of inhaled prostaglandins in patients with ARDS. Chest 2015;147(6):1510–1522.
    OpenUrlPubMed
  126. 126.↵
    1. Siddiqui S,
    2. Salahuddin N,
    3. Zubair S,
    4. Yousuf M,
    5. Azam l,
    6. Gilani AH
    . Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS: a randomized clinical trial. Open J Anesthesiol 2013;3:109–115.
    OpenUrl
  127. 127.↵
    1. Ammar MA,
    2. Bauer SR,
    3. Bass SN,
    4. Sasidhar M,
    5. Mullin R,
    6. Lam SW
    . Noninferiority of inhaled epoprostenol to inhaled nitric oxide for the treatment of ARDS. Ann Pharmacother 2015;49(10):1105–1112.
    OpenUrlCrossRefPubMed
  128. 128.↵
    1. Dhand R
    . Special problems in aerosol delivery: artificial airways. Respir Care 2000;45(6):636–645.
    OpenUrlPubMed
  129. 129.↵
    1. Crogan SJ,
    2. Bishop MJ
    . Delivery efficiency of metered dose aerosols given via endotracheal tubes. Anesthesiology 1989;70(6):1008–1010.
    OpenUrlPubMedWeb of Science
  130. 130.↵
    1. Ahrens RC,
    2. Ries RA,
    3. Popendorf W,
    4. Wiese JA
    . The delivery of therapeutic aerosols through endotracheal tubes. Pediatr Pulmonol 1986;2(1):19–26.
    OpenUrlPubMedWeb of Science
  131. 131.↵
    1. Takaya T,
    2. Takeyama K,
    3. Takiguchi M
    . The efficiency of beta2-agonist delivery through tracheal tubes with the metered-dose inhaler: an in vitro study. J Anesth 2002;16(4):284–288.
    OpenUrlPubMed
  132. 132.↵
    1. Ari A,
    2. Harwood RJ,
    3. Sheard MM,
    4. Fink JB
    . Pressurized metered-dose inhalers versus nebulizers in the treatment of mechanically ventilated subjects with artificial airways: an in vitro study. Respir Care 2015;60(11):1570–1574.
    OpenUrlAbstract/FREE Full Text
  133. 133.↵
    1. Piccuito CM,
    2. Hess DR
    . Albuterol delivery via tracheostomy tubes. Respir Care 2005;50(8):1071–1076.
    OpenUrlAbstract/FREE Full Text
  134. 134.↵
    1. Pitance L,
    2. Vecellio L,
    3. Delval G,
    4. Reychler G,
    5. Reychler H,
    6. Liistro G
    . Aerosol delivery through tracheostomy tubes: an in vitro study. J Aerosol Med Pulm Drug Deliv 2013;26(2):76–83.
    OpenUrlPubMed
  135. 135.↵
    1. Fuller H,
    2. Dolovich M,
    3. Turpie F,
    4. Posmituck G,
    5. Wong Pack W,
    6. Newhouse M
    . Aerosol deposition to the lungs by MDI in ventilated patients: endotracheal tubes vs tracheostomy. Chest 1990;98(2 Suppl):27S.
    OpenUrl
  136. 136.↵
    1. Fuller HD,
    2. Dolovich MB,
    3. Chambers C,
    4. Newhouse MT
    . Aerosol delivery during mechanical ventilation: a predictive in vitro lung model. J Aerosol Med 1992;5(4):251–259.
    OpenUrl
  137. 137.↵
    1. Garner SS,
    2. Wiest DB,
    3. Bradley JW
    . Aerosol delivery by metered-dose inhaler with a pediatric mechanical ventilatory circuit model. Pharmacotherapy 1994;14(2):210–214.
    OpenUrlPubMed
  138. 138.↵
    1. Lange CF,
    2. Finlay WH
    . Overcoming the adverse effect of humidity in aerosol delivery via pressurized metered-dose inhalers during mechanical ventilation. Am J Respir Crit Care Med 2000;161(5):1614–1618.
    OpenUrlPubMed
  139. 139.↵
    1. Lin HL,
    2. Fink JB,
    3. Zhou Y,
    4. Cheng Y-S
    . Influence of moisture accumulation in inline spacer on delivery of metered dose inhaler through mechanical ventilation. Respir Care 2009;54(10):1336–1341.
    OpenUrlAbstract/FREE Full Text
  140. 140.↵
    1. Wilkes AR
    . Heat and moisture exchangers: structure and function. Respir Care Clin N Am 1998;4(2):261–279.
    OpenUrlPubMed
  141. 141.↵
    1. Ari A,
    2. Fink JB
    . Factors affecting bronchodilator delivery in mechanically ventilated patients. Nurs Crit Care 2010;15(4):192–203.
    OpenUrlPubMed
  142. 142.↵
    1. Ari A,
    2. Alwadeai KS,
    3. Fink JB
    . Effects of heat and moisture exchangers and exhaled humidity on aerosol deposition in a simulated ventilator-dependent adult lung model. Respir Care 2017;62(5):538–543.
    OpenUrlAbstract/FREE Full Text
  143. 143.↵
    1. Svartengren M,
    2. Anderson M,
    3. Philipson K,
    4. Camner P
    . Human lung deposition of particles suspended in air or in helium/oxygen mixture. Exp Lung Res 1989;15(4):575–585.
    OpenUrlCrossRefPubMedWeb of Science
  144. 144.↵
    1. Habib DM,
    2. Garner SS,
    3. Brandeburg S
    . Effect of helium-oxygen on delivery of albuterol in a pediatric, volume-cycled, ventilated lung model. Pharmacotherapy 1999;19(2):143–149.
    OpenUrlCrossRefPubMedWeb of Science
  145. 145.↵
    1. Goode ML,
    2. Fink JB,
    3. Dhand R,
    4. Tobin MJ
    . Improvement in aerosol delivery with helium-oxygen mixtures during mechanical ventilation. Am J Respir Crit Care Med 2001;163(1):109–114.
    OpenUrlCrossRefPubMedWeb of Science
  146. 146.↵
    1. Hess DR,
    2. Acosta FL,
    3. Ritz RH,
    4. Kacmarek RM,
    5. Camargo CA Jr.
    . The effect of heliox on nebulizer function using a beta-agonist bronchodilator. Chest 1999;115(1):184–189.
    OpenUrlCrossRefPubMedWeb of Science
  147. 147.↵
    1. Tassaux D,
    2. Jolliet P,
    3. Thouret M,
    4. Roeseler J,
    5. Dorne R,
    6. Chevrolet JC
    . Calibration of seven ICU ventilators for mechanical ventilation with helium-oxygen mixtures. Am J Respir Crit Care Med 1999;160(1):22–32.
    OpenUrlCrossRefPubMedWeb of Science
  148. 148.↵
    1. Guerin C,
    2. Fassier T,
    3. Bayle F,
    4. Lemasson S,
    5. Richard JC
    . Inhaled bronchodilator administration during mechanical ventilation: how to optimize it, and for which clinical benefit. J Aerosol Med Pulm Drug Deliv 2008;21(1):85–95.
    OpenUrlPubMed
  149. 149.↵
    1. Colebourn CL,
    2. Barber V,
    3. Young JD
    . Use of helium-oxygen mixture in adult patients presenting with exacerbations of asthma and chronic obstructive pulmonary disease: a systematic review. Anesthesia 2007;62(1):34–42.
    OpenUrlCrossRefPubMedWeb of Science
  150. 150.↵
    1. Chowdhury MM,
    2. McKenzie SA,
    3. Pearson CC,
    4. Carr S,
    5. Pao C,
    6. Shah AR,
    7. et al
    . Heliox therapy in bronchiolitis: phase III multicenter double-blind randomized controlled trial. Pediatrics 2013;131(4):661–669.
    OpenUrlAbstract/FREE Full Text
  151. 151.↵
    1. Hurford WE,
    2. Cheifetz IM
    . Respiratory controversies in the critical care setting. Should heliox be used for mechanically ventilated patients? Respir Care 52(5):582–591, 2007; discussion 591-594.
    OpenUrlAbstract/FREE Full Text
  152. 152.↵
    1. Danin PE,
    2. Girou E,
    3. Legrand P,
    4. Louis B,
    5. Fodil R,
    6. Christov C,
    7. et al
    . Description and microbiology of endotracheal tube biofilm in mechanically ventilated subjects. Respir Care 2015;60(1):21–29.
    OpenUrlAbstract/FREE Full Text
  153. 153.↵
    1. Longest PW,
    2. Azimi M,
    3. Golshahi L,
    4. Hindle M
    . Improving aerosol drug delivery during invasive mechanical ventilation with redesigned components. Respir Care 2014;59(5):686–698.
    OpenUrlAbstract/FREE Full Text
  154. 154.↵
    1. Manthous CA,
    2. Khamiees M
    . In-line suction catheters may impede aerosol delivery to patients receiving mechanical ventilation. Chest 2000;118(3):884–885.
    OpenUrlCrossRefPubMed
  155. 155.↵
    1. Taherian S,
    2. Rahai H,
    3. Gomez BZ,
    4. Waddington T,
    5. Bonifacio JR
    . Tracheal stenosis: a CFD approach for evaluation of drug delivery. Presented at ASME 2015 International Mechanical Engineering Congress and Exposition, held November 13-19, 2015, in Houston, Texas.
  156. 156.↵
    1. Grosz AH,
    2. Jacobs IN,
    3. Cho C,
    4. Schears GJ
    . Use of helium-oxygen mixtures to relieve upper airway obstruction in a pediatric population. Laryngoscope 2001;111(9):1512–1514.
    OpenUrlCrossRefPubMedWeb of Science
  157. 157.↵
    1. Hess DR,
    2. Dillman C,
    3. Kacmarek RM
    . In vitro evaluation of aerosol bronchodilator delivery during mechanical ventilation: pressure-control vs. volume control ventilation. Intensive Care Med 2003;29(7):1145–1150.
    OpenUrlCrossRefPubMedWeb of Science
  158. 158.↵
    1. Guérin C,
    2. Durand PG,
    3. Pereira C,
    4. Richard JC,
    5. Poupelin JC,
    6. Lemasson S,
    7. et al
    . Effects of inhaled fenoterol and positive end-expiratory pressure on the respiratory mechanics of patients with chronic obstructive pulmonary disease. Can Respir J 2005;12(6):329–335.
    OpenUrlPubMed
  159. 159.↵
    1. Bates J,
    2. Milic-Emili J
    . The flow interruption technique for measuring respiratory resistance. J Crit Care 1991;6(4):227–238.
    OpenUrl
  160. 160.↵
    1. Kondili E,
    2. Alexopoulou C,
    3. Prinianakis G,
    4. Xirouchaki N,
    5. Vaporidi K,
    6. Georgopoulos D
    . Effect of albuterol on expiratory resistance in mechanically ventilated patients. Respir Care 2011;56(5):626–632.
    OpenUrlAbstract/FREE Full Text
  161. 161.↵
    1. Dhand R
    . Ventilator graphics and respiratory mechanics in the patient with obstructive lung disease. Respir Care 50(2):246–259, 2005; discussion 259-261.
    OpenUrlAbstract/FREE Full Text
  162. 162.↵
    1. Shorr AF,
    2. Zilberberg MD
    . The answer for inhaled antibiotics in pneumonia is still blowing in the wind. Chest 2017;151(6):1201–1203.
    OpenUrl
  163. 163.↵
    1. Anzueto A,
    2. Baughman RP,
    3. Guntupalli K,
    4. Weg JG,
    5. Wiedemann HP,
    6. Raventós AA,
    7. et al
    . Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N Engl J Med 1996;334(22):1417–1421.
    OpenUrlCrossRefPubMedWeb of Science
  164. 164.↵
    1. Weg JG,
    2. Balk RA,
    3. Tharrat S,
    4. Jenkinson SG,
    5. Shah JB,
    6. Zaccardelli D,
    7. et al
    . Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome. JAMA 1994;272(18):1433–1438.
    OpenUrlCrossRefPubMedWeb of Science
  165. 165.↵
    1. Zandstra DF,
    2. Stoutenbeek CP,
    3. Miranda DR
    . The effect of mucolytic and bronchodilator aerosol therapy on airway resistance in mechanically ventilated patients. Intensive Care Med 1985;11(6):316–318.
    OpenUrlPubMed
  166. 166.↵
    1. Fernandez R,
    2. Sole J,
    3. Blanch L,
    4. Artigas A
    . The effect of short term instillation of a mucolytic agent (Mesna) on airway resistance in mechanically ventilated patients. Chest 1995;107(4):1101–1106.
    OpenUrlCrossRefPubMed
  167. 167.↵
    1. Voelker KG,
    2. Chetty KG,
    3. Mahutte CK
    . Resolution of recurrent atelectasis in spinal cord patients with administration of recombinant human DNase. Intensive Care Med 1996;22(6):582–584.
    OpenUrlPubMedWeb of Science
  168. 168.↵
    1. Claudius C,
    2. Perner A,
    3. Moller MH
    . Nebulised dornase alfa versus placebo or hypertonic saline in adult critically ill patients: a systematic review of randomized clinical trials with meta-analysis and trial sequential analysis. Systematic Reviews 2015;4:153.
    OpenUrl
  169. 169.↵
    1. Nava S,
    2. Compagnoni ML
    . Controlled short-term trial of fluticasone propionate in ventilator-dependent patients with COPD. Chest 2000;118(4):990–999.
    OpenUrlCrossRefPubMedWeb of Science
  170. 170.↵
    1. Chen WC,
    2. Chen HH,
    3. Chiang CH,
    4. Lee YC,
    5. Yang KY
    . Effect of salmeterol/fluticasone combination on the dynamic changes of lung mechanics in mechanically ventilated COPD patients: a prospective pilot study. Int J Chron Obstruct Pulmon Dis 2016;27(11):167–174.
    OpenUrl
  171. 171.↵
    1. Ernst P,
    2. Gonzalez A,
    3. Brassard P,
    4. Suissa S
    . Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176(2):162–166.
    OpenUrlCrossRefPubMedWeb of Science
  172. 172.↵
    1. Price D,
    2. Yawn B,
    3. Brusselle G,
    4. Rossi A
    . Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J 2013;22(1):92–100.
    OpenUrlCrossRefPubMed
  173. 173.↵
    1. Tejerina E,
    2. Frutos-Vivar F,
    3. Restrepo MI,
    4. Anzueto A,
    5. Abroug F,
    6. Palizas F,
    7. et al
    . Incidence, risk factors, and outcome of ventilator-associated pneumonia. J Crit Care 2006;21(1):56–65.
    OpenUrlCrossRefPubMedWeb of Science
  174. 174.↵
    1. Festic E,
    2. Carr GE,
    3. Cartin-Ceba R,
    4. Hinds RF,
    5. Banner-Goodspeed V,
    6. Bansal V,
    7. et al
    . Randomized clinical trial of a combination of an inhaled corticosteroid and beta-agonist in patients at risk of developing the acute respiratory distress syndrome. Crit Care Med 2017;45(5):798–805.
    OpenUrl
  175. 175.↵
    1. Jaillette E,
    2. Nseir S
    . Relationship between inhaled β2-agonists and ventilator-associated pneumonia: a cohort study. Crit Care Med 2011;39(4):725–730.
    OpenUrlCrossRefPubMed
  176. 176.↵
    1. Dhand R
    . The role of aerosolized antimicrobials in the treatment of ventilator-associated pneumonia. Respir Care 2007;52(7):866–884.
    OpenUrlAbstract/FREE Full Text
  177. 177.↵
    1. Eschenbacher WL,
    2. Boushey HA,
    3. Sheppard D
    . Alteration in osmolarity of inhaled aerosols causes bronchoconstriction and cough, but absence of permeant anion causes cough alone. Am Rev Respir Dis 1984;129(2):211–215.
    OpenUrlPubMedWeb of Science
  178. 178.
    1. Godden DJ,
    2. Borland C,
    3. Lowry R,
    4. Higgenbottam TW
    . Chemical specificity of coughing in man. Clin Sci (Lond) 1986;70(3):301–306.
    OpenUrlCrossRefPubMed
  179. 179.↵
    1. Lowry RH,
    2. Wood AM,
    3. Higgenbottam TW
    . Effects of pH and osmolarity on aerosol-induced cough in normal volunteers. Clin Sci (Lond) 1988;74(4):373–376.
    OpenUrlCrossRefPubMed
  180. 180.↵
    1. Miszkiel KA,
    2. Beasley R,
    3. Rafferty P,
    4. Holgate ST
    . The contribution of histamine release to bronchoconstriction provoked by inhaled benzalkonium chloride in asthma. Br J Clin Pharmacol 1988;25(2):157–163.
    OpenUrlPubMedWeb of Science
  181. 181.
    1. Miszkiel KA,
    2. Beasley R,
    3. Holgate ST
    . The influence of ipratropium bromide and sodium cromoglycate on benzalkonium chloride-induced bronchoconstriction in asthma. Br J Clin Pharamcol 1988;26(3):295–301.
    OpenUrl
  182. 182.
    1. Downes H,
    2. Hirshman CA
    . Calcium chelators increase airway responsiveness. J Appl Physiol 1985;59(1):92–95.
    OpenUrlAbstract/FREE Full Text
  183. 183.↵
    1. Beasley R,
    2. Rafferty P,
    3. Holgate ST
    . Adverse reactions to the nondrug constituents of nebuliser solutions. Br J Clin Pharmacol 1988;25(3):283–287.
    OpenUrlPubMedWeb of Science
  184. 184.↵
    1. MacNeish CF,
    2. Meisner D,
    3. Thibert R,
    4. Kelemen S,
    5. Vadas EB,
    6. Coates AL
    . A comparison of pulmonary availability between Ventolin (albuterol) nebules and Ventolin (albuterol) respirator solution. Chest 1997;111(1):204–208.
    OpenUrlCrossRefPubMedWeb of Science
  185. 185.↵
    1. Berlinski A,
    2. Waldrep JC
    . Nebulized drug admixtures: effect on aerosol characteristics and albuterol output. J Aerosol Med 2006;19(4):484–490.
    OpenUrlCrossRefPubMedWeb of Science
  186. 186.↵
    1. Coates AL,
    2. MacNeish CF,
    3. Meisner D,
    4. Kelemen S,
    5. Thibert R,
    6. MacDonald J,
    7. Vadas E
    . The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols. Chest 1997;111(5):1206–1212.
    OpenUrlCrossRefPubMedWeb of Science
  187. 187.↵
    1. Flament MP,
    2. Leterme P,
    3. Burnouf T,
    4. Gayot A
    . Influence of formulation on jet nebulisation quality of alpha 1 protease inhibitor. Int J Pharm 1999;178(1):101–109.
    OpenUrlPubMed
  188. 188.↵
    1. McKenzie JE,
    2. Cruz-Rivera M
    . Compatibility of budesonide inhalation suspension with four nebulizing solutions. Ann Pharmacother 2004;38(6):967–972.
    OpenUrlCrossRefPubMed
  189. 189.
    1. Lee TY,
    2. Chen CM,
    3. Lee CN,
    4. Chiang YC,
    5. Chen HY
    . Compatibility and osmolality of inhaled N-acetylcysteine nebulizing solution with fenoterol and ipratropium. Am J Health Syst Pharm 2005;62(8):828–833.
    OpenUrlAbstract/FREE Full Text
  190. 190.↵
    1. Kamin W,
    2. Schwabe A,
    3. Kramer I
    . Inhalation solutions: which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers. J Cyst Fibros 2006;5(4):205–213.
    OpenUrlCrossRefPubMedWeb of Science
  191. 191.↵
    1. Akapo S,
    2. Gupta J,
    3. Martinez E,
    4. McCrea C,
    5. Ye L,
    6. Roach M
    . Compatibility and aerosol characteristics of formoterol fumarate mixed with other nebulizing solutions. Ann Pharmacother 2008;42(10):1416–1424.
    OpenUrlCrossRefPubMed
  192. 192.↵
    1. Fok TF,
    2. Monkman S,
    3. Dolovich M,
    4. Gray S,
    5. Coates G,
    6. Paes B,
    7. et al
    . Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia. Pediatr Pulmonol 1996;21(5):301–309.
    OpenUrlCrossRefPubMedWeb of Science
  193. 193.↵
    1. Sivakumar D,
    2. Bosque E,
    3. Goldman SL
    . Bronchodilator delivered by metered dose inhaler and spacer improves respiratory system compliance more than nebulizer-delivered bronchodilator in ventilated premature infants. Pediatr Pulmonol 1999;27(3):208–212.
    OpenUrlPubMed
  194. 194.↵
    1. Fok TF,
    2. Lam K,
    3. Ng PC,
    4. Leung TF,
    5. So HK,
    6. Cheung KL,
    7. Wong W
    . Delivery of salbutamol to nonventilated preterm infants by metered-dose inhaler, jet nebulizer, and ultrasonic nebulizer. Eur Respir J 1998;12(1):159–164.
    OpenUrlAbstract
  195. 195.↵
    1. Fayon M,
    2. Tayara N,
    3. Germain C,
    4. Choukroun ML,
    5. De La Roque ED,
    6. Chêne G,
    7. et al
    . Efficacy and tolerance of high-dose inhaled ipratropium bromide vs. terbutaline in intubated premature human neonates. Neonatology 2007;91(3):167–173.
    OpenUrlCrossRefPubMedWeb of Science
  196. 196.↵
    1. Cameron D,
    2. Clay M,
    3. Silverman M
    . Evaluation of nebulizers for use in neonatal ventilator circuits. Crit Care Med 1990;18(8):866–870.
    OpenUrlPubMedWeb of Science
  197. 197.↵
    1. Wildhaber JH,
    2. Hayden MJ,
    3. Dore ND,
    4. Devadason SG,
    5. LeSouëf PN
    . Salbutamol delivery from a hydrofluoralkane pressurized metered-dose inhaler in pediatric ventilator circuits. Chest 1998;113(1):186–191.
    OpenUrlCrossRefPubMed
  198. 198.↵
    1. Graham DR,
    2. Chamberlain MJ,
    3. Hutton L,
    4. King M,
    5. Morgan WK
    . Inhaled particle deposition and body habitus. Br J Ind Med 1990;47(1):38–43.
    OpenUrlPubMedWeb of Science
  199. 199.↵
    1. Ari A,
    2. Harwood RJ,
    3. Sheard MM,
    4. Fink JB
    . An in vitro evaluation of aerosol delivery through tracheostomy and endotracheal tubes using different interfaces. Respir Care 2012;57(7):1066–1070.
    OpenUrlAbstract/FREE Full Text
  200. 200.↵
    1. Mir M,
    2. Dhand R
    . Nebulized drug delivery in patients breathing spontaneously through an artificial airway. Respir Care 2012;57(7):1195–1196.
    OpenUrlFREE Full Text
  201. 201.↵
    1. Brower RG,
    2. Matthay MA,
    3. Morris A,
    4. Schoenfeld D,
    5. Thompson BT,
    6. Wheeler A
    Acute Respiratory Distress Syndrome Network, Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The acute respiratory distress syndrome network. N Engl J Med 2000;342(18):1301–1308.
    OpenUrlCrossRefPubMedWeb of Science
  202. 202.↵
    1. Dubosky MN,
    2. Chen YF,
    3. Henriksen ME,
    4. Vines DL
    . Vibrating mesh nebulizer compared with metered-dose inhaler in mechanically ventilated subjects. Respir Care 2017;62(4):391–395.
    OpenUrlAbstract/FREE Full Text
  203. 203.↵
    1. Walton JS,
    2. Fears R,
    3. Burt N,
    4. Dorman HB
    . Intraoperative breathing circuit obstruction caused by nebulization of albuterol. Anesth Analg 1999;89(3):650–651.
    OpenUrlCrossRefPubMedWeb of Science
  204. 204.↵
    1. Tonnelier A,
    2. Lellouche F,
    3. Bouchard PA,
    4. L'Her E
    . Impact of humidification and nebulization during expiratory limb protection: an experimental bench study. Respir Care 2013;58(8):1315–1322.
    OpenUrlAbstract/FREE Full Text
  205. 205.↵
    1. Davies JBS,
    2. Bromilow J
    . Bacterial filter obstruction with the use of ultrasonic nebulisation. Anaesthesia 2011;66(5):394–395.
    OpenUrlCrossRefPubMed
  206. 206.↵
    1. Cunningham S,
    2. Prasad A,
    3. Collyer L,
    4. Carr S,
    5. Lynn IB,
    6. Wallis C
    . Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch Dis Child 2001;84(5):432–433.
    OpenUrlAbstract/FREE Full Text
  207. 207.↵
    1. Dodd ME,
    2. Abbott J,
    3. Maddison J,
    4. Moorcroft AJ,
    5. Webb AK
    . Effect of tonicity of nebulized colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax 1997;52(7):656–658.
    OpenUrlAbstract
  208. 208.↵
    1. Quieffin J,
    2. Hunter J,
    3. Schechter MT,
    4. Lawson L,
    5. Ruedy J,
    6. Pare P,
    7. Montaner JS
    . Aerosol pentamidine-induced bronchoconstriction: predictive factors and preventive therapy. Chest 1991;100(3):624–627.
    OpenUrlCrossRefPubMed
  209. 209.↵
    1. Dally MB,
    2. Kurrle S,
    3. Breslin ABX
    . Ventilatory effects of aerosol gentamicin. Thorax 1978;33(1):54–56.
    OpenUrlAbstract/FREE Full Text
  210. 210.↵
    1. Alothman GA,
    2. Alsaadi MM,
    3. Ho BL,
    4. Ho SL,
    5. Dupuis A,
    6. Corey M,
    7. Coates AL
    . Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin. Chest 2002;122(3):930–934.
    OpenUrlCrossRefPubMedWeb of Science
  211. 211.↵
    1. Prober CG,
    2. Walson PD,
    3. Jones J
    . Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs. Pediatrics 2000;106(6):E89.
    OpenUrlCrossRefPubMed
  212. 212.↵
    1. Christiani DC,
    2. Kern DG
    . Asthma risk and occupation as a respiratory therapist. Am Rev Respir Dis 1993;148(3):671–674.
    OpenUrlPubMedWeb of Science
  213. 213.↵
    1. Carnathan B,
    2. Martin B,
    3. Colice G
    . Second hand (S)-albuterol: RT exposure risk following racemic albuterol. Respir Care 2001;46:1084.
    OpenUrl
  214. 214.↵
    1. Eames I,
    2. Tang JW,
    3. Li Y,
    4. Wilson P
    . Airborne transmission of disease in hospitals. J R Soc Interface 2009;6(suppl 6):S697–702.
    OpenUrlAbstract/FREE Full Text
  215. 215.↵
    1. Hui DS,
    2. Chow BK,
    3. Chu LC,
    4. Ng SS,
    5. Hall SD,
    6. Gin T,
    7. Chan MT
    . Exhaled air droplet dispersion during application of a jet nebulizer. Chest 2009;135(3):648–654.
    OpenUrlCrossRefPubMedWeb of Science
  216. 216.↵
    1. Dunne PJ
    . Economic aspects of introducing new nebulizer technology. Respir Care 2002;47(11):1321–1331.
    OpenUrlPubMed
  217. 217.↵
    1. Brocklebank D,
    2. Ram F,
    3. Wright J,
    4. Barry P,
    5. Cates C,
    6. Davies L,
    7. et al
    . Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess 2001;5(26):1–149.
    OpenUrlPubMed
Back to top

In this issue

 

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Related Articles

Cited By...

Keywords